- There were about 589 Million Adults Around the World Living with Diabetes in 2024, with 90% Having Type 2 Diabetes.
- Past Studies Have Shown That People Who Have Type 2 Diabetes Are at A Higher Risk of Developing Dementia.
- A New Study Has Found That Ken It Comes To The Neuroprotive Abilities of Diabetes Medications, People Taking Glp-1 agonists had a significantly Lower Cumulative Risk of Developing Dementia, When Combased to Metformin Users.
The International Diabetes Federation Reports there were about 589 Million Adults Around the World Living with Diabetes in 2024, with 90% of these have has 2 diabetes.
Past Studies Show That People Who Have Type 2 Diabetes – A Chronic Condition where the body does not use its insulin properly – are at A Higher Risk of Developing Dementia.
“Type 2 diabetes is not only a Metabolic Disorder But also a Major Risk Factor Formentia, particularly Alzheimer’s Disease and Other
“The Risk of Developing Dementia is Approximately 1.7 Times Higher in Individuals with Type 2 Diabetes Than In the General Population.
He is first and co-senior author of a new study recently published in the journal bmj open diabetes research & care.
The Study Found that when comparing the neuroprotective abilities of two diabetes medications-Metformin and Glucagon-Like peptide-1 receiver agonists (LPG-1 agonists)-Participants Taking LP Metformin
Comparing GLP-1S, Head-To-Head Metformin
For This Study, Researchers Analyzed Electronic Health Record Data from The Global Health Research Network Trinetx. Scientists Focused on Data from More than 87,000 People with an average age of 58 Who Had Type 2 Diabetes and Were prescribed Eithher Metformin Or a LPG-1 agonist, to track Any Dementia Development.
“Although Metformin is Widely Accepted as the first-line therapy for type 2 diabetes, its effects on cognitive outcomes have been inconsistent,” Wu Said. “We Aimed to Investigate Whether Starting with A Second-Line Agent Like Like Like GLP-1 agonists might confer Greater Protection Effects Against Dementia.
“No real-beorld study has directly compared LPG-1 agonists and metformin Head-to-Head for Dementia Prevention,” I have continued. “IF GLP-1 Agonists Superior Neuroprotective Benefits Show, This Coulnge the Traditional Treatment Paradigm and Support Initiating Therapy with Glp-1 agonists in selected patients.”
“GLP-1 agonists have demonstrated mechanisms that include reducing neuroinflamation, cerebral enhancing glycose metabolism, and improving synaptic plasticity,” Wu Added. “Given these Benefits, it is imperative that we continue exploring their Broader Therapeutic potential Beyond Glucose Lowering.”
LGP-1S LOWER ALZHEIMER’S RISK BY 12% COMPARTED TO METFORMIN
At the study’s conclusion, wu and his team Found that study participants Taking Glp-1 agonists had a significantly Lower Cumulative Risk of Developing Dementia-Namely, 10%-with an enters of abut 2.5%.
By Comparison, The Dementia Incondence Rate for Those Taking Metformin was almost 5%.
“This Nearly Twofold Difference in Dementia Incondence is clinically significant,” Wu Explained.
“It suggests that initiating treatment with glyp-1 agonists may be more effective than metformin in rearmentia risk Among individuals with type 2 diabetes. Given the high prevalence of both diabetes and dementia in aging populans, this strategy may reduce long-term public public health public health public health public health public Burdens, Including Healthcare Costs, Caregiver Stress, and Institutionalization Needs. ”
-Szu-Yuan Wu, MD, MPH, PHD
The Researcher Team Also Discovered That Study Participants Taking LP-1 agonists had 25% Lower Risk of Developing Non-Vascular Dementias and 12% Lower Chance of Developing Alzheimer’s Disease, Combased to participants Taking Metformin.
“BeSe Subtype-Specific Findings Reinforce The Mechanistic Rationale for LPG-1 agonists in neuroprotect,” Wu Said. “They are Known to reduce Amyloid-Beta Accumulation, Suppress Tau Hyperphosphorylation, Improves Integrity, and Lower Systemic Inflammation.”
“It is Effects are not only theoretical; Clinical Trials of Agents Like Liraglutide Have Shown Cognitive Improvements In Patieves With Early Alzheimer’s Disease. OUR Results Support ThatSe Biological Actions May Translate Into Meaningful Risk Risk Risk Risk In Real-Wor. Population, ”He Detailed.
A Novel, Effective Way of Lowering Dementia Risk?
MNT Had the Opportunity To Speak With Michael Snyder, MD, FACS, FASMBS, Medical Director of the Bariatric Surgery Center at Rose Medical Center, Founder and Director of the Denver Center for Bariatric Surgery Foundation, and In-House Obesity Specialist for Futurhealth, About This Study.
Snyder, who was not involved in the research, commented that before weeks are significant to an introduction to a novel and seemingly Extremely Effective Way of Decreating the Risk of Type 2 Diabetes Related Dementia, Specifically, Alzheimer’s Disease and Nonvascular Dementia.
“Early Research has suggested that GLP-1 Medications May offer powerful benefits for Brain Health,” I explained.
“Obesity, Insulin Resistance, and Type 2 Diabetes are All Known to Increase The Risk of Dementia, Larngely Due to Their Role In Driving Inflammation, Vascular Damage, and Other Long-Term Stressors On The Brain. By targeting amese Underlying issues, GLP-1S, which are already Widely used to treat obesity and diabetes, May offer indirect protection cognitive desire, ”Snyder poined out.
“In Addition, Emerging Evidence Shows That GLP-1S May Have Direct Neurological Effects, Influence Memory, Cognitive Function, and Neuroinflammation,” I have continued. “Although Promising, Long-Term Studies and Clinical Trials Are Needed to Fully Understand Glp-1s Impact On The Brain. With That Said, LPG-1S COULD PLAY A PIVOTAL Role in Preventing or Slowing Neurodegenerative Neurodefire, Marking A Major Step forward forward in The Future of Brain Health. “
More Research Needed for Definitive Conclusions
MNT Also Spoke to Jennifer Cheng, Do, Chief of Endocrinology at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, About This Research.
“As an endocrinologist Who Treats Type 2 Diabetes on a regular basis, I Found the Study to Be Thought Provoking and an Interesting Avenue of Research,” Cheng, Who Likewise was not involved in the Research, Commeable. “The cognitive complications of diabetes can be significant and life webilitating. The Protective Effect for Diabetes Is Promising and May Help with Treatment Decions in the Future. It is an interesting method of researcher and can lead to further discoveries.”
“We are discovering new effects of the LPG-1 medications and it is interesting to see the positive protection efforts. Patients with diabetes do have increased risk for neurological disorders vascular vascular issues and dementia. This is just an observational study so there Cause of the Decueed Risk of Alzheimer’s and/or Dementia. “
– Jennifer Cheng, do
“For Research Next Steps, It Would Be Interesting to see the new LP-1 Medications, and Effects of the LPG-1s, Studied to see if it is definitive,” Cheng Added. “We Cannot Conclude That Based on An Observational Study That The LP-1 was The Primary Agent To Help Prevent the Cognitive Complications of Diabetes, But It Does Warrant Further Research, specially with new GLP-1 medications in revealing.”
